A5026771200- Asthma and respiratory diseases
- Chronic Obstructive Pulmonary Disease (COPD) Research
- Respiratory Support and Mechanisms
- Respiratory and Cough-Related Research
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Pulmonary Hypertension Research and Treatments
- Eosinophilic Esophagitis
- School Health and Nursing Education
- Pediatric health and respiratory diseases
- Cardiac Health and Mental Health
- Inhalation and Respiratory Drug Delivery
- Neonatal Respiratory Health Research
Royal Alexandra Hospital
2006-2022
Small studies have suggested that inhaled corticosteroids can suppress systemic inflammation in chronic obstructive pulmonary disease (COPD).To determine the effect of with or without long-acting beta(2)-adrenergic agonist on biomarkers inflammation.We conducted a double-blind randomized placebo-controlled trial across 11 centers (n = 289 patients FEV(1) 47.8 +/- 16.2% predicted) to compare effects fluticasone alone combination salmeterol against placebo circulating over 4 weeks. The primary...
Rationale: Pulmonary rehabilitation improves dyspnea and exercise capacity in idiopathic pulmonary fibrosis (IPF); however, it is unknown whether breathing high amounts of oxygen during training leads to further benefits.Objectives: Herein, we describe the design High Oxygen Delivery Preserve Exercise Capacity IPF Patients Treated with Nintedanib study (the HOPE-IPF study). The primary objective this determine physiological perceptual impact levels patients who are receiving antifibrotic...
RATIONALE: There is a need to characterize the real-world impact of benralizumab, an anti-interleukin-5 receptor alpha antibody, for add-on maintenance therapy patients with severe eosinophilic asthma.
Abstract Background Systemic inflammation is associated with various complications in chronic obstructive pulmonary disease including weight loss, cachexia, osteoporosis, cancer and cardiovascular diseases. Inhaled corticosteroids attenuate airway inflammation, reduce exacerbations, improve mortality disease. Whether inhaled by themselves or combination a long-acting β 2 -adrenoceptor agonist repress systemic unknown. The Advair Biomarkers COPD (ABC) study will determine whether the effects...